
Oxford BioMedica appoints Alex Lewis to strategy role
pharmafile | June 8, 2011 | Appointment | Research and Development | appointment, research and development
Oxford, UK-based gene therapy company Oxford BioMedica has appointed Dr Alex Lewis as director of corporate activities and strategy, and as a member of its senior management team.
As a result he steps down from the board of Oxford BioMedica and in his place Dr Paul Blake will become chairman of Oxford BioMedica’s remuneration committee.
Alex has spent over 24 years in medical research and drug development and first joined Oxford BioMedica’s board in April 2008.
During this time he was also director of transactions and due diligence at The Datamonitor Group until June 2009 and then became director of Lewis Healthcare Consultants.
Prior to this, he was head of the partnering and due diligence practice of Wood Mackenzie research consultants.
Oxford BioMedica’s chief executive John Dawson said: “Alex is an expert addition to the senior management team as we continue to build Oxford BioMedica as a successful biopharmaceutical company founded on the development and commercialisation of products derived from innovative technology platforms. Alex’s knowledge and advice will also be instrumental in evaluating other value-enhancing opportunities to grow the business.”
Related Content

PlasmidFactory founder Dr. Martin Schleef honoured with the NRW Innovation Award 2025
The founder and long-standing CEO of PlasmidFactory, Dr. Martin Schleef, was honoured in Düsseldorf with …

AAX Biotech announces collaboration for cardiovascular antibody therapy
Swedish biotech firm AAX Biotech has entered a new collaboration focused on the development of …

Research finds tablet effective in slowing progression of Alzheimer’s disease over 18 months
TauRx Pharmaceutics reports that hydromethylthionine mesylate (HMTM) could be an oral treatment for slowing the …






